Detalhe da pesquisa
1.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Prostate
; 84(3): 292-302, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964482
2.
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Invest New Drugs
; 42(1): 145-159, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324085
3.
Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.
J Pathol
; 260(1): 43-55, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36752189
4.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(10): 1094-1108, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37714168
5.
The Value of Phenotypic Precision Medicine in Prostate Cancer.
Oncologist
; 28(2): 93-104, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200788
6.
Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board.
Oncologist
; 28(1): 33-39, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35962742
7.
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer.
Future Oncol
; 2023 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36705526
8.
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Prostate
; 82(13): 1237-1247, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675470
9.
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
Prostate
; 82(7): 858-866, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35286730
10.
Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.
Clin Adv Hematol Oncol
; 20(4): 227-238, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35389387
11.
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
Cancer
; 127(16): 2954-2965, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951180
12.
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
J Urol
; 205(5): 1361-1371, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356529
13.
Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.
J Gen Intern Med
; 36(1): 92-99, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32875501
14.
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
J Natl Compr Canc Netw
; 19(2): 134-143, 2021 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33545689
15.
Molecular determinants for enzalutamide-induced transcription in prostate cancer.
Nucleic Acids Res
; 47(19): 10104-10114, 2019 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31501863
16.
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
Int J Urol
; 28(7): 765-773, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33955599
17.
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Genes Chromosomes Cancer
; 59(4): 225-239, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31705765
18.
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
Prostate
; 79(10): 1106-1116, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31045266
19.
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
Prostate
; 79(15): 1752-1761, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31497882
20.
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
Cancer
; 125(23): 4172-4180, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31483485